Author

DA Proia

Observed names: D Proia, Proia D.

Observed institutions: Brigham and Women's Hospital, Fox Chase Cancer Center, Tufts Medical Center, Memorial Sloan Kettering Cancer Center, Cornell University, Royal Bournemouth Hospital, Churchill Hospital, Institut Jules Bordet, University of Oxford, University of Chicago, Dana-Farber Cancer Institute, Instituto Nacional de Enfermedades Neoplásicas, Duke Medical Center, Oxford University Hospitals NHS Trust, Whitehead Institute for Biomedical Research, Synta Pharmaceuticals (United States), Dana-Farber Brigham Cancer Center

OpenAlex ID: A5032661607

Abstract P2-16-23: The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative breast cancer (TNBC)

2013 · A Awada, N Spector, et al. · Cancer Research · 4

P3-17-05: Beyond HER2 and Hormonal Agents: The Heat Shock Protein 90 Inhibitor Ganetespib as a Potential New Breast Cancer Therapy.

2011 · JC Friedland, J Sang, et al. · Cancer Research · 3

Abstract 1731: Preclinical testing demonstrates strong activity of STA-12-8666, an HSP90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)

2015 · Anna Gaponova, AS Nikonova, et al. · Cancer Research · 1

Abstract PD5-3: Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer

2013 · DA Proia, C Zhang, et al. · Cancer Research

Abstract P4-16-05: Hsp90 inhibition potentiates chemotherapy effectiveness in triple negative breast cancer: Role of glucocorticoid receptor signaling

2013 · A Agyeman, W Jun, et al. · Cancer Research

Abstract OT3-2-05: Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer

2013 · NU Lin, L Whitesell, et al. · Cancer Research

Works count: 7

Citation count: 8

H-index: 2

I10-index: